Saturday, July 11, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “treatment”

2,520 pharma patents match "treatment" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,520
Index total 30,257
Page 30 / 105

Quick answer

This filtered view shows 2,520 pharmaceutical patents matching "treatment" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,520 results for “treatment” · 30,257 patents in full index Clear search

  1. US 11198724

    Treatment of staphylococcal disorders

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  2. US 11197833

    Fortified CBD oil for treatment of PTSD

    Bright Green Corporation · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  3. US 11197822

    Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract

    The Regents of the University of California · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  4. US 11197869

    Istaroxime-containing intravenous formulation for the treatment of acute heart failure (AHF)

    Windtree Therapeutics, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  5. US 11197821

    Formulations for treatment of dry eye disease

    Aldeyra Therapeutics, Inc. · Granted Dec 14, 2021 · Expires Dec 9, 2041

    granted

  6. US 11191774

    Drug formulations for cancer treatment

    The Regents of the University of California · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  7. US 11191750

    Use of mTOR inhibitors for treatment of familial adenomatous polyposis

    The Board of Regents of the University of Texas System · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  8. US 11191780

    Extracellular matrix compositions for the treatment of cancer or immunological diseases

    Adaptive Biologix, Inc. · Granted Dec 7, 2021 · Expires Dec 2, 2041

    granted

  9. US 11186566

    Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator

    Vertex Pharmaceuticals Incorporated · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  10. US 11185572

    Mesenchymal stem cells for the treatment of CNS diseases

    BRAINSTORM CELL THERAPEUTICS LTD. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  11. US 11185564

    Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

    Krystal Biotech, Inc. · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  12. US 11185554

    Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease

    The Board of Regents of the University of Texas System · Granted Nov 30, 2021 · Expires Nov 25, 2041

    granted

  13. US 11179328

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  14. US 11179327

    Compositions and methods for the treatment of presbyopia

    Lenz Therapeutics, Inc. · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  15. US 11181536

    Methods for monitoring treatment of chronic liver disease

    The Regents of the University of Colorado, a Body Corporate · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  16. US 11179384

    Treatment of nonalcoholic fatty liver disease

    TAKEDA GMBH · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  17. US 11180518

    Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma

    Ludwig-Maximilians-Universitat Munchen · Granted Nov 23, 2021 · Expires Nov 18, 2041

    granted

  18. US 11174272

    1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

    Takeda Pharmaceutical Company Limited · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted

  19. US 11174469

    Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders

    CRISPR THERAPEUTICS AG · Granted Nov 16, 2021 · Expires Nov 11, 2041

    granted

  20. US 11166964

    Treatment for modulating gut microbiota

    GALMED RESEARCH AND DEVELOPMENT LTD · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted

  21. US 11166949

    NURR1 activation in the treatment of metabolic disorders and as an exercise mimetic

    The Board of Regents of the University of Texas System · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted

  22. US 11168305

    Methods for the treatment of degenerative disc disease

    DiscGenics, Inc. · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted

  23. US 11168325

    Methods for treatment of polycystic kidney disease

    The Board of Regents of the University of Texas System · Granted Nov 9, 2021 · Expires Nov 4, 2041

    granted

  24. US 11160850

    Compositions of human prothrombin and activated factor X for improving hemostasis in the treatment of bleeding disorders

    Takeda Pharmaceutical Company Limited · Granted Nov 2, 2021 · Expires Oct 28, 2041

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.